ANKUR DRUGS AND PHARMA LIMITED

Registered Office: 20th Floor, Lotus Business Park, Off. Andheri Link Road, Andheri (West), Mumbai- 400 053

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2010

(Rs. lakh)

Sr. No.	Particulars	Quarter ended on 30.09.2010 (Un-audited)	Quarter ended on 30.09.2009 (Un-audited)	Half- Year ended on 30.09.2010 (Un-audited)	Half Year ended on 30.09.2009 (Un-audited)	Year ended on 31.03.2010 (Audited)
1	Net Sales/Income from Operations	**27,274.82**	**26,925.13**	**55,257.29**	54,570.28	106,740.76
2	Other Income	**18.64**	**42.63**	**40.27**	74.52	198.98
3	Total Income	**27,293.46**	**26,967.76**	**55,297.56**	54,644.80	106,939.74
4	**Total Expenditure**					
	a) (Increase)/decrease in stock	**656.04**	**1,096.83**	**(717.61)**	3,420.55	(372.26)
	b) Materials Consumed	**18,618.92**	**18,760.02**	**40,309.02**	37,599.25	79,950.60
	c) Labour and Staff Cost	**715.27**	**518.15**	**1,275.52**	975.74	2,322.73
	d) Manufacturing, administrative & selling expenses	**1,298.13**	**843.05**	**2,569.72**	2,088.23	3,620.46
5.	**PROFIT BEFORE DEPRECIATION, FINANCE COST AND TAX**	**6,005.10**	**5,749.71**	**11,860.91**	**10,561.03**	21,418.21
6.	Depreciation	**990.55**	**595.05**	**1,969.09**	1,177.84	2,663.98
7.	**PROFIT BEFORE FINANCE COST, EXCHANGE FLUCTUATION AND TAX**	**5,014.55**	**5,154.66**	**9,891.82**	**9,383.19**	18,754.23
8	a) Interest and Financial Charges	**2,562.24**	**1,864.21**	**5,081.11**	3,844.18	8,074.98
	b) Provision for Exchange difference on Foreign Currency Loans	**-**	**-**	**-**	(962.13)	(1,543.07)
	c) Provision for premium on redemption of FCCBs	**227.45**	**282.18**	**452.43**	421.38	343.72
9.	**PROFIT BEFORE EXCEPTIONAL ITEM AND TAX**	**2,224.86**	**3,008.27**	**4,358.28**	**6,079.76**	11,878.60
10.	**Add/(Less): Exceptional Item:**					
	Provision for Diminution in value of investment	**-**	**(76.01)**	**-**	(76.01)	(121.43)
11	**PROFIT BEFORE TAX**	**2,224.86**	**3,084.28**	**4,358.28**	**6,155.77**	12,000.03
12	**Provision for Taxation**					
	-Current Tax	**440.00**	**524.00**	**863.00**	1,046.00	1,705.36
	-Deferred Tax/(Assets)	**-**	**75.00**	**-**	150.00	1,201.40
	-Fringe Benefit Tax	**-**	**-**	**-**	-	-
	-Excess provision for Income-Tax and FBT for Earlier year	**-**	**-**	**-**	-	475.51
13	**Net Profit After Tax (11-12)**	**1,784.86**	**2,485.28**	**3,495.28**	**4,959.77**	8,617.76
14	Paid-up Equity Share Capital	**1,934.16**	**1,901.54**	**1,934.16**	**1,901.54**	1,861.54
15	Reserves & Surplus (Excluding Revaluation Reserve)	**-**	**-**		-	33,794.03
16	Earning per share (Rs.) (Basic/Diluted)					
	-Basic	**9.23**	**13.35**	18.07	26.64	44.56
	-Diluted	**7.09**	**11.25**	**13.88**	21.88	30.33
17	Aggregate of Non-Promoter Shareholding					
	-Number of Shares	**14,436,242**	**11,899,947**	**14,436,242**	**11,899,947**	12,221,110
	-Percentage of Shareholding (%)	**74.64**	**62.58**	**74.64**	**62.58**	63.19
18	Promoters and promoter group shareholding**					
	a) Pledged/Encumbered					
	-Number of Shares	3,849,000	2,972,750	3,849,000	2,972,750	3,683,000
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	78.47	41.78	78.47	41.78	51.72
	-Percentage of shares (as a % of the total share capital of the company)	19.90	15.63	19.90	15.63	19.04
	b) Non-encumbered					
	-Number of Shares	1,056,348	4,142,694	1,056,348	4,142,694	3,437,480
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	21.53	58.22	21.53	58.22	48.28
	-Percentage of shares (as a % of the total share capital of the company)	5.46	21.79	5.46	21.79	17.77

NOTES:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 14th November, 2010
2. The Company has completed the Capex. However the capacity utilisaton for sterile section is low and will pick up gradually.
3. The company has provided for premium on redemption of Foreign Currency Convertible Bonds as per terms and condions of offer.
4. Investor complaints received and disposed off during quarter ended September 30, 2010:

Complaints pending at the beginning of the quarter	3
Complaints received during the quarter	NIL
Disposal of complaints	NIL
Complaints lying unresolved at the end of the quarter	3

6. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17 disclosure of segment information is not applicable.

For **ANKUR DRUGS AND PHARMA LIMITED**

sd/-

Place : Mumbai.
Dated: 14th November,2010.

PURNANDU JAIN
Chairman and Managing Director